Govoni V, Granieri E, Tola M R, Casetta I, Monetti V C, Fainardi E, Paolino E
Institute of Neurology Clinic, University of Ferrara, Italy.
Acta Neurol Scand. 1994 Jun;89(6):433-8. doi: 10.1111/j.1600-0404.1994.tb02662.x.
The period prevalence rate for anti-parkinson drugs (APD) use was reported in the Local Health Service of Ferrara (USL 31), Northern Italy, in 1988 (resident population: 177,000 inhabitants).
The study was performed through the analysis of the complete list of APD prescriptions in the USL 31 area provided by the computerized archives of USL 31 and the identification code of the patients which is unique for each resident of USL 31. The patients treated with neuroleptics known to be potential parkinsonism-inducing drugs were excluded.
The period prevalence rate for APD users was 456.9 per 100,000 population. The prevalence rate for dopa derivatives users was 391.3 per 100,000. The prevalence did not varied between rural and urban zones of USL 31 both for APD and dopa derivatives users. A higher prevalence was obtained in a small rural commune of USL 31 both for APD users (758.5 per 100,000) and dopa derivatives users (718.6 per 100,000) than in the other 4 communes in which the study area is subdivided.
The reported prevalence could provide information on the occurrence of most parkinsonisms in the study area and some suggestion on the role of possible environmental factors.
1988年，意大利北部费拉拉地方卫生服务局（USL 31）报告了抗帕金森药物（APD）的期间患病率（常住人口：17.7万居民）。
本研究通过分析USL 31计算机存档提供的USL 31地区APD处方完整清单以及USL 31每位居民唯一的患者识别码来进行。已知为潜在帕金森症诱发药物的抗精神病药治疗的患者被排除。
APD使用者的期间患病率为每10万人456.9例。多巴衍生物使用者的患病率为每10万人391.3例。对于APD和多巴衍生物使用者，USL 31的农村和城市地区患病率没有差异。USL 31的一个小农村公社中，APD使用者（每10万人758.5例）和多巴衍生物使用者（每10万人718.6例）的患病率高于研究区域划分的其他4个公社。
报告的患病率可为研究区域大多数帕金森症的发生情况提供信息，并对可能的环境因素的作用提供一些建议。
